U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07551505) titled 'Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)' on April 19.
Brief Summary: The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) [Lp(a)].
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Dyslipidemias
Intervention:
DRUG: BSA204
BSA204 Injection
DRUG: Placbo
Placbo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....